Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain.
Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain.
comments(0)
5-min edit window · permanent after that